Conformis to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Bedford, Mass. – January 7, 2014 – Conformis, Inc., a medical device company pioneering patient-specific orthopedic implants, will present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, California. Dr. Philipp Lang, Chairman and CEO of Conformis, will discuss the company’s proprietary technology for patient-specific implants and instruments, its unique Just-In-Time (JIT) delivery model and novel, innovative, 3-D additive manufacturing technologies. Dr. Lang’s presentation will begin at 4 PM (PT) on Wednesday, January 15, 2014.
About Conformis, Inc.
Conformis, Inc. is a privately-held medical device company that is pioneering a patient-specific approach to orthopedic implants and instrumentation. Its proprietary technology is supported by more than 375 patents and patent applications. Conformis’ award winning partial and total knee replacement solutions, the iUni® G2, iDuo® G2 and iTotal® G2, are individually designed for each patient. Potential advantages compared to traditional off-the-shelf implants include faster recovery, shorter hospital stay, less blood loss, more bone preservation, and better functional outcomes. Conformis products are provided in a pre-sterilized single package delivery system that can help hospitals reduce costs associated with instrument re-sterilization and result in faster set-up, procedure and turnover time. The iUni® G2, iDuo® G2 and iTotal® G2, have been cleared by the U.S. FDA and are CE Marked in Europe.
Conformis is the leader in additive manufacturing in the orthopedic and medical device space. Conformis is the only orthopedic company that offers Just-In-Time (JIT) manufacturing with a single-package delivery system, resulting in greatly enhanced use of working capital.
Conformis technology is broadly applicable to all joints. The company is expanding into new applications and indications.
New Implant Technology, A New Twist On Knee Replacement
The Cape Cod Chronicle: ConforMIS, is breaking new ground in the field of knee replacements by offering something never seen before: customized knee implants designed and manufactured for each individual patient, with no two quite alike.
Four-Year Data from the UK National Joint Registry Highlights High Survivorship in Patients Treated with the Conformis iTotal CR
Data Shows a Low Cumulative Percent Revision of 0.5% for Conformis Patients vs 1.9% for all Total Knee Replacement Patients